2024-03-29T15:23:03Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/2124202022-06-02T10:45:30Zcom_10261_64com_10261_1col_10261_317
Vasculogenic mimicry: Become an endothelial cell “But not so much”
Fernández-Cortés, Mónica
Delgado-Bellido, Daniel
Oliver, Francisco Javier
Ministerio de Economía y Competitividad (España)
Ministerio de Ciencia y Tecnología (España)
Instituto de Salud Carlos III
vasculogenic mimicry, tumor microenvironment, metastasis, VE-cadherin, anti-angiogenesis therapeutic failure, cell plasticity
Blood vessels supply all body tissues with nutrients and oxygen, take away waste products and allow the arrival of immune cells and other cells (pericytes, smooth muscle cells) that form part of these vessels around the principal endothelial cells. Vasculogenic mimicry (VM) is a tumor blood supply system that takes place independently of angiogenesis or endothelial cells, and is associated with poor survival in cancer patients. Aberrant expression of VE-cadherin has been strongly associated with VM. Even more, VE-cadherin has constitutively high phosphorylation levels on the residue of Y658 in human malignant melanoma cells. In this review we focus on non-endothelial VE-cadherin and its post-translational modifications as a crucial component in the development of tumor VM, highlighting the signaling pathways that lead to their pseudo-endothelial and stem-like phenotype and the role of tumor microenvironment. We discuss the importance of the tumor microenvironment in VM acquisition, and describe the most recent therapeutic targets that have been proposed for the repression of VM.
This work was supported by the grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, Fundación Domingo Martínez and the Spanish Ministry of Science and Technology RTI2018-098968-B-I00 and CIBERONC ISCIII CB16/12/00421 to FO.
2020-05-28T08:30:03Z
2020-05-28T08:30:03Z
2019
2020-05-28T08:30:04Z
artículo
http://purl.org/coar/resource_type/c_6501
doi: 10.3389/fonc.2019.00803
e-issn: 2234-943X
Frontiers in Oncology 9 (2019)
http://hdl.handle.net/10261/212420
10.3389/fonc.2019.00803
http://dx.doi.org/10.13039/501100003329
http://dx.doi.org/10.13039/501100006280
http://dx.doi.org/10.13039/501100004587
31508365
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2015-70520-R
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-098968-B-I00
Publisher's version
http://dx.doi.org/10.3389/fonc.2019.00803
Sí
open
Frontiers Media